[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-447915-105":59,"doc-detail-447915-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multidisciplinary-management-of-urethral-melanoma-article","Multidisciplinary management of urethral melanoma - Article","","Primary urethral melanoma is a rare, aggressive malignancy with scarce therapeutic evidence and often delayed diagnosis. A 54-year-old woman with urethral melanoma underwent local excision, subsequent margin re-excision, and laparoscopic right inguinal lymphadenectomy for a palpable node, followed by adjuvant pembrolizumab. The patient showed favorable short-term evolution with no recurrence at six months. Clinical, molecular, and treatment characteristics are reviewed, highlighting the importance of initial surgery, variable immunotherapy benefit, absence of standardized protocols, and the need for individualized multidisciplinary management and further research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multidisciplinary-management-of-urethral-melanoma-article/447915/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multidisciplinary-management-of-urethral-melanoma-article/447915.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-04","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is primary urethral melanoma difficult to manage therapeutically?","Question",{"text":112,"@type":113},"Therapeutic management lacks clear consensus because reported cases are scarce, and outcomes vary across multimodal approaches. Advanced disease also shows molecular differences that reduce effectiveness of some targeted and conventional immunotherapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatments were used in the presented case?",{"text":117,"@type":113},"The patient received local excision, margin re-excision, laparoscopic right inguinal lymphadenectomy for a palpable node, and then adjuvant pembrolizumab.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular findings supported the diagnosis in this case?",{"text":121,"@type":113},"Genetic testing showed a positive c-KIT mutation and absence of BRAF mutation at codon 600. Immunohistochemistry supported melanocytic origin with positivity for Melan-A, S100, HMB-45, p16, and PRAME.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},447915,1791118179,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Urology Case Reports 64 (2026) 103319  \nContents lists available at ScienceDirect  \nUrology Case Reports  \njournal [homepage:](homepage: www.elsevier.com/locate/eucr)[ www.elsevier.com/locate/eucr](homepage: www.elsevier.com/locate/eucr)  \n| Oncology\u003Cbr>Multidisciplinary management of urethral melanoma☆\u003Cbr>Alba Rubia Escribanoa,b,c,* , Beatriz G´omez Gonz´alez a,b,c, Alejandro Hevia Feliú a,b,c, Bego˜na Fern´andez Martínez a,b,c, Ana Moreno Reboiroa,b,c, Alejandra Navarro Pi˜neiro a,b,c, Ignacio Gonz´alez-Valc´arcel De Torres a,b,c, Ana Isabel Linares Quevedoa,b,c,\u003Cbr>Jos´e Manuel De La Morena Gallego a,b,c\u003Cbr>a Hospital Universitario Infanta Sofía, Paseo de Europa, 34, San Sebastia´n de los Reyes, 2870, Madrid, Spain b Universidad Europea de Madrid, Paseo de Europa, 34, San Sebasti´an de los Reyes, 2870, Madrid, Spain\u003Cbr>c Fundaci´on para la Investigaci´on e Innovaci´onBiom´edica del Hospital Universitario Infanta Sofía, Paseo de Europa, 34, San Sebastia´n de los Reyes, 2870, Madrid, Spain |  |  | |\n| --- | --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Urethral melanoma\u003Cbr>Mucosal melanoma\u003Cbr>Molecular mutations\u003Cbr>Immunotherapy\u003Cbr>Inguinal lymphadenectomy |  | Primary urethral melanoma is a rare and aggressive neoplasm with limited therapeutic evidence and typically delayed diagnosis.\u003Cbr>We report the case of a 54-year-old woman diagnosed with urethral melanoma, treated by local excision, subsequent margin re-excision, and laparoscopic right inguinal lymphadenectomy for a palpable node, followed by adjuvant pembrolizumab, achieving favorable evolution and no recurrence at six months.\u003Cbr>Clinical, molecular, and therapeutic aspects of this entity are reviewed, emphasizing the role of initial surgical excision, limited response to immunotherapy, and lack of standardized protocols. Optimal management requires an individualized multidisciplinary approach and further research to improve outcomes. |  |\n\n1. Introduction  \nMelanoma is a malignant neoplasm derived from melanocytes, which, although most frequently found in the skin, may also arise from mucosal surfaces such as the oral, nasal, genital, and anorectal mucosae.1  \nPrimary urethral melanoma represents a rare entity (4 % of urethral cancers), with distinct clinical, molecular, and therapeutic characteristics compared to cutaneous melanoma. Diagnosis is often delayed, with a high incidence of nodal involvement and distant metastases, contributing to a poor prognosis.1  \nTherapeutic management lacks a clear consensus due to the scarcity of reported cases and is generally based on multimodal strategies adapted from other melanoma subtypes, though with variable outcomes. In advanced disease, molecular differences from cutaneous melanoma limit the efficacy of targeted therapies and conventional immunotherapy.2  \nThis article reviews the clinical, molecular, diagnostic, and therapeutic characteristics of urethral melanoma, emphasizing the need for  \npersonalized approaches and further research to optimize management.  \n2. Case presentation  \nWe present the case of a 54-year-old woman with a history of nasal polyposis, chronic rhinitis, and pollen allergy treated with antihistamines, and a previous right inguinal hernioplasty, who was evaluated for a friable urethral lesion of several months’ duration with progressive growth.  \nPhysical examination revealed a polypoid lesion arising from the anterior urethral wall, approximately 3 cm (cm) in size, non-pigmented and pinkish in color. Surgical excision was performed under the initial impression of a urethral caruncle.  \nHistopathological analysis showed urethral mucosa lined by squamous epithelium with a basal proliferation of cells arranged in solid nests infiltrating the submucosa, marked pleomorphism, and irregular nuclei with prominent nucleoli (Fig. 1). The mitotic index was high (13 mitoses/2 mm2), and the proliferative index, measured by nuclear Ki-67 expression, was 15 %(Fig. 2).  \n☆ Thi","cbCaibXdCTt0Iumk","https://ap.wps.com/l/cbCaibXdCTt0Iumk","pdf",2452288,"English","# Introduction\n# Case presentation","[{\"question\":\"Why is primary urethral melanoma difficult to manage therapeutically?\",\"answer\":\"Therapeutic management lacks clear consensus because reported cases are scarce, and outcomes vary across multimodal approaches. Advanced disease also shows molecular differences that reduce effectiveness of some targeted and conventional immunotherapies.\"},{\"question\":\"What treatments were used in the presented case?\",\"answer\":\"The patient received local excision, margin re-excision, laparoscopic right inguinal lymphadenectomy for a palpable node, and then adjuvant pembrolizumab.\"},{\"question\":\"What molecular findings supported the diagnosis in this case?\",\"answer\":\"Genetic testing showed a positive c-KIT mutation and absence of BRAF mutation at codon 600. Immunohistochemistry supported melanocytic origin with positivity for Melan-A, S100, HMB-45, p16, and PRAME.\"}]","Multidisciplinary management of urethral melanoma - Article | PDF",1790724024]